Related Experiment Video

Updated: Jan 9, 2026

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
07:08

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

1.3K

New Treatment Options for Pancreatic Neuroendocrine Tumors: A Narrative Review

Agnieszka Romanowicz1, Marta Fudalej1,2, Alicja Asendrych-Woźniak1

  • 1Department of Oncology, National Medical Institute of the Ministry of the Interior and Administration, 02-507 Warsaw, Poland.

Cancers
|December 11, 2025
PubMed

Insights

Pancreatic neuroendocrine neoplasms (PanNENs) are diverse cancers. This review covers current and emerging systemic treatments for advanced PanNETs to improve patient outcomes.

Area of Science:

  • Oncology
  • Endocrinology

Background:

  • Pancreatic neuroendocrine neoplasms (PanNENs) are a heterogeneous group of tumors.
  • Most PanNETs are non-functional and express somatostatin receptors (SSTRs).
  • Optimal treatment sequencing for advanced PanNETs remains under investigation.

Purpose of the Study:

  • To review current systemic therapies for advanced PanNETs.
  • To discuss novel and emerging treatment strategies for PanNETs.

Main Methods:

  • Literature review of established and investigational therapies for PanNETs.
  • Discussion of systemic treatment options including targeted therapies and immunotherapies.

Main Results:

  • Several treatment options exist for advanced PanNETs, but optimal sequencing is not defined.
  • New therapeutic agents are under development, including immune checkpoint inhibitors and next-generation peptide receptor radionuclide therapy.

Conclusions:

  • A multidisciplinary approach is crucial for evaluating systemic treatment options in PanNETs.
  • Ongoing clinical trials and research into new drugs aim to improve outcomes for advanced PanNETs.
Keywords:
immunotherapynarrative reviewpancreatic neuroendocrine tumorspeptide receptor radionuclide therapytargeted therapy

More Related Videos

Robotic Enucleation of an Intra-Pancreatic Insulinoma in the Pancreatic Head05:42

Robotic Enucleation of an Intra-Pancreatic Insulinoma in the Pancreatic Head

Published on: January 3, 2020

8.7K

Related Concept Videos

Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
286
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
518
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K